Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kelly K Bree

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
European Urology Oncology|May 3, 2021
Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Guérin Therapy OutcomesPatrick J Hensley, Kelly K Bree, Nathan Brooks, et al.
The Journal of Urology|June 30, 2022
Reply by AuthorsKelly K Bree, Patrick J Hensley, Niyati Lobo, et al.
BJU International|January 23, 2021
Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancerKelly K Bree, Patrick J Hensley, Nathan A Brooks, et al.
European Urology Oncology|February 1, 2024
Association of Age with Non-muscle-invasive Bladder Cancer: Unearthing a Biological Basis for Epidemiological Disparities?Niyati Lobo, Zhigang Duan, Akshay Sood, et al.
The Journal of Urology|June 29, 2021
Progression of Disease after Bacillus Calmette-Guérin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical CystectomyPatrick J Hensley, Kelly K Bree, Matthew T Campbell, et al.
The Journal of Urology|August 10, 2021
Reply by AuthorsPatrick J Hensley, Kelly K Bree, Matthew T Campbell, et al.
The Journal of Urology|November 3, 2023
Long-Term Oncological Outcomes in Patients Diagnosed With Nonmetastatic Plasmacytoid Variant of Bladder Cancer: A 20-Year University of Texas MD Anderson Cancer Center ExperienceAkshay Sood, Jan K Rudzinski, Craig V Labbate, et al.
European Urology Oncology|June 3, 2026
Survival Outcomes of a Smoking Cessation Treatment Program After Diagnosis of Bladder CancerLandan P MacDonald, George Kypriotakis, Maher Karam-Hage, et al.
European Urology|October 4, 2025
Cost-effectiveness Analysis of Treatments for Bacillus Calmette-Guérin-unresponsive Carcinoma in Situ of the BladderAmanda A Myers, Ruchika Talwar, Zhigang Duan, et al.
European Urology Oncology|October 11, 2025
Intermediate-risk Non-muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification, Management Strategies, and Clinical Trial Design from the International Bladder Cancer GroupRoger Li, Patrick J Hensley, Marko Babjuk, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
European Urology Oncology|May 3, 2021
Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Guérin Therapy OutcomesPatrick J Hensley, Kelly K Bree, Nathan Brooks, et al.
The Journal of Urology|June 30, 2022
Reply by AuthorsKelly K Bree, Patrick J Hensley, Niyati Lobo, et al.
BJU International|January 23, 2021
Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancerKelly K Bree, Patrick J Hensley, Nathan A Brooks, et al.
European Urology Oncology|February 1, 2024
Association of Age with Non-muscle-invasive Bladder Cancer: Unearthing a Biological Basis for Epidemiological Disparities?Niyati Lobo, Zhigang Duan, Akshay Sood, et al.
The Journal of Urology|June 29, 2021
Progression of Disease after Bacillus Calmette-Guérin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical CystectomyPatrick J Hensley, Kelly K Bree, Matthew T Campbell, et al.
The Journal of Urology|August 10, 2021
Reply by AuthorsPatrick J Hensley, Kelly K Bree, Matthew T Campbell, et al.
The Journal of Urology|November 3, 2023
Long-Term Oncological Outcomes in Patients Diagnosed With Nonmetastatic Plasmacytoid Variant of Bladder Cancer: A 20-Year University of Texas MD Anderson Cancer Center ExperienceAkshay Sood, Jan K Rudzinski, Craig V Labbate, et al.
European Urology Oncology|June 3, 2026
Survival Outcomes of a Smoking Cessation Treatment Program After Diagnosis of Bladder CancerLandan P MacDonald, George Kypriotakis, Maher Karam-Hage, et al.
European Urology|October 4, 2025
Cost-effectiveness Analysis of Treatments for Bacillus Calmette-Guérin-unresponsive Carcinoma in Situ of the BladderAmanda A Myers, Ruchika Talwar, Zhigang Duan, et al.
European Urology Oncology|October 11, 2025
Intermediate-risk Non-muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification, Management Strategies, and Clinical Trial Design from the International Bladder Cancer GroupRoger Li, Patrick J Hensley, Marko Babjuk, et al.
Pageof 5